Davis Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$564 Buy
4
+1
+33% +$143 ﹤0.01% 608
2026
Q2
$368 Buy
+3
New +$313 ﹤0.01% 683

Other funds holding PTGX

Davis Capital Management's PTGX Position: Q3 2026 in Review

Davis Capital Management increased its Protagonist Therapeutics (PTGX) stake by 33% in Q3 2026, buying an estimated $143 and bringing the position to 4 shares worth $564. The position accounts for ﹤0.01% of the portfolio, ranked #608.

Davis Capital Management first reported a position in PTGX in Q2 2026 and has held it in 2 quarters since. 380 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • Davis Capital Management held 4 shares of Protagonist Therapeutics worth $564 as of Q3 2026.
  • Davis Capital Management bought 1 Protagonist Therapeutics share in Q3 2026, an estimated $143.
  • Protagonist Therapeutics made up ﹤0.01% of Davis Capital Management's portfolio in Q3 2026, its #608 holding.
  • Davis Capital Management first reported a position in Protagonist Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 380 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Davis Capital Management's 13F filing for Q3 2026, filed 8 Oct 2026.